DESCRIPTION

CARBOplatin for Injection USP is supplied as a sterile, lyophilized white powder available in single-dose vials containing 50 mg or 150 mg or 450 mg of carboplatin for administration by intravenous infusion. Each vial contains equal parts by weight of carboplatin and mannitol. Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. The chemical name for carboplatin is platinum, diammine [1,1-cyclobutane-dicarboxylato(2-)-0,0’],(SP-4-2), and has the following structural formula:

Carboplatin is a crystalline powder with the molecular formula of C6H12N2O4Pt and a molecular weight of 371.25. It is soluble in water at a rate of approximately 14 mg/mL, and the pH of a 1% solution is 5-7. It is virtually insoluble in ethanol, acetone, and dimethylacetamide.

CLINICAL PHARMACOLOGY

Carboplatin, like cisplatin, produces predominantly interstrand DNA crosslinks rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.

In patients with creatinine clearances of about 60 mL/min or greater, plasma levels of intact carboplatin decay in a biphasic manner after a 30-minute intravenous infusion of 300 to 500 mg/m2 of CARBOplatin for Injection USP. The initial plasma half-life (alpha) was found to be 1.1 to 2 hours (N = 6), and the postdistribution plasma half-life (beta) was found to be 2.6 to 5.9 hours (N = 6). The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively. The Cmax values and areas under the plasma concentration vs. time curves from 0 to infinity (AUC inf) increase linearly with dose, although the increase was slightly more than dose proportional. Carboplatin, therefore, exhibits linear pharmacokinetics over the dosing range studied (300-500 mg/m2).

Carboplatin is not bound to plasma proteins. No significant quantities of protein-free, ultrafilterable platinum-containing species other than carboplatin are present in plasma. However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.

The major route of elimination of carboplatin is renal excretion. Patients with creatinine clearances of approximately 60 mL/min or greater excrete 65% of the dose in the urine within 12 hours and 71% of the dose within 24 hours. All of the platinum in the 24-hour urine is present as carboplatin. Only 3% to 5% of the administered platinum is excreted in the urine between 24 and 96 hours. There are insufficient data to determine whether biliary excretion occurs.

In patients with creatinine clearances below 60 mL/min the total body and renal clearances of carboplatin decrease as the creatinine clearance decreases. Carboplatin dosages should therefore be reduced in these patients (see DOSAGE AND ADMINISTRATION).

The primary determinant of CARBOplatin for Injection USP clearance is glomerular filtration rate (GFR) and this parameter of renal function is often decreased in elderly patients. Dosing formulas incorporating estimates of GFR (see DOSAGE AND ADMINISTRATION) to provide predictable CARBOplatin for Injection USP plasma AUCs should be used in elderly patients to minimize the risk of toxicity.

CLINICAL STUDIES

Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: In two prospectively randomized, controlled studies conducted by the National Cancer Institute of Canada, Clinical Trials Group (NCIC) and the Southwest Oncology Group (SWOG), 789 chemotherapy naive patients with advanced ovarian cancer were treated with carboplatin or cisplatin, both in combination with cyclophosphamide every 28 days for six courses before surgical reevaluation. The following results were obtained from both studies:

COMPARATIVE EFFICACY:

* 114 Carboplatin and 109 Cisplatin patients did not undergo second look surgery in NCIC study. 90 Carboplatin and 106 Cisplatin patients did not undergo second look surgery in SWOG study.
Overview of Pivotal Trials
	NCIC	SWOG
Number of patients randomized	447	342
Median age (years)	60	62
Dose of cisplatin	75 mg/m2	100 mg/m2
Dose of carboplatin	300 mg/m2	300 mg/m2
Dose of CYTOXAN®	600 mg/m2	600 mg/m2
(cyclophosphamide, USP)
Residual tumor < 2 cm	39%	14%
(number of patients)	(174/447)	(49/342)
Clinical Response in Measurable Disease Patients
	NCIC	SWOG
Carboplatin	60%	58%
(number of patients)	(48/80)	(48/83)
Cisplatin	58%	43%
(number of patients)	(49/85)	(33/76)
95% C.I. of difference	(-13.9%, 18.6%)	(-2.3%, 31.1%)
(Carboplatin - Cisplatin)
Pathologic Complete Response*
	NCIC	SWOG
Carboplatin	11%	10%
(number of patients)	(24/224)	(17/171)
Cisplatin	15%	10%
(number of patients)	(33/223)	(17/171)
95% C.I. of difference	(-10.7%, 2.5%)	(-6.9%, 6.9%)
(Carboplatin - Cisplatin)

* Kaplan-Meier Estimates Unrelated deaths occurring in the absence of progression were counted as events (progression) in this analysis. † Analysis adjusted for factors found to be of prognostic significance were consistent with unadjusted analysis.
Progression-Free Survival (PFS)
	NCIC	SWOG
Median
Carboplatin	59 weeks	49 weeks
Cisplatin	61 weeks	47 weeks
2-year PFS*
Carboplatin	31%	21%
Cisplatin	31%	21%
95% C.I. of difference	(-9.3, 8.7)	(-9.0, 9.4)
(Carboplatin - Cisplatin)
3-year PFS*
Carboplatin	19%	8%
Cisplatin	23%	14%
95% C.I. of difference	(-11.5, 4.5)	(-14.1, 0.3)
(Carboplatin - Cisplatin)
Hazard Ratio†	1.10	1.02
95% C.I.	(0.89, 1.35)	(0.81, 1.29)
(Carboplatin - Cisplatin)

* Kaplan-Meier Estimates † Analysis adjusted for factors found to be of prognostic significance were consistent with unadjusted analysis.
Survival
	NCIC	SWOG
Median
Carboplatin	110 weeks	86 weeks
Cisplatin	99 weeks	79 weeks
2-year Survival*
Carboplatin	51.9%	40.2%
Cisplatin	48.4%	39.0%
95% C.I. of difference	(-6.2, 13.2)	(-9.8, 12.2)
(Carboplatin - Cisplatin)
3-year Survival*
Carboplatin	34.6%	18.3%
Cisplatin	33.1%	24.9%
95% C.I. of difference	(-7.7, 10.7)	(-15.9, 2.7)
(Carboplatin - Cisplatin)
Hazard Ratio†	0.98	1.01
95% C.I.	(0.78, 1.23)	(0.78, 1.30)
(Carboplatin - Cisplatin)

COMPARATIVE TOXICITY: The pattern of toxicity exerted by the CARBOplatin for Injection USP - containing regimen was significantly different from that of the cisplatin-containing combinations. Differences between the two studies may be explained by different cisplatin dosages and by different supportive care. The CARBOplatin for Injection USP - containing regimen induced significantly more thrombocytopenia and, in one study, significantly more leukopenia and more need for transfusional support. The cisplatin-containing regimen produced significantly more anemia in one study. However, no significant differences occurred in incidences of infections and hemorrhagic episodes.

Non-hematologic toxicities (emesis, neurotoxicity, ototoxicity, renal toxicity, hypomagnesemia, and alopecia) were significantly more frequent in the cisplatin-containing arms.

ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER NCIC STUDY

* Values are in percent of evaluable patients † n.s. = not significant, p > 0.05 ‡ May have been affected by cyclophosphamide dosage delivered
		Carboplatin Arm Percent*	Cisplatin Arm Percent*	P-Values†
Bone Marrow
Thrombocytopenia	< 100,000/mm3	70	29	< 0.001
	< 50,000/mm3	41	6	< 0.001
Neutropenia	< 2,000 cells/mm3	97	96	n.s.
	< 1,000 cells/mm3	81	79	n.s.
Leukopenia	< 4,000 cells/mm3	98	97	n.s.
	< 2,000 cells/mm3	68	52	0.001
Anemia	< 11 g/dL	91	91	n.s.
	< 8 g/dL	18	12	n.s.
Infections		14	12	n.s.
Bleeding		10	4	n.s.
Transfusions		42	31	0.018
Gastrointestinal
Nausea and vomiting		93	98	0.010
Vomiting		84	97	< 0.001
Other GI side effects		50	62	0.013
Neurologic
Peripheral neuropathies		16	42	< 0.001
Ototoxicity		13	33	< 0.001
Other sensory side effects		6	10	n.s.
Central neurotoxicity		28	40	0.009
Renal
Serum creatinine elevations		5	13	0.006
Blood urea elevations		17	31	< 0.001
Hepatic
Bilirubin elevations		5	3	n.s.
SGOT elevations		17	13	n.s.
Alkaline phosphatase elevations		-	-	-
Electrolytes loss
Sodium		10	20	0.005
Potassium		16	22	n.s.
Calcium		16	19	n.s.
Magnesium		63	88	< 0.001
Other side effects
Pain		36	37	n.s.
Asthenia		40	33	n.s.
Cardiovascular		15	19	n.s.
Respiratory		8	9	n.s.
Allergic		12	9	n.s.
Genitourinary		10	10	n.s.
Alopecia‡		50	62	0.017
Mucositis		10	9	n.s.

ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER SWOG STUDY

* Values are in percent of evaluable patients † n.s. = not significant, p > 0.05 ‡ May have been affected by cyclophosphamide dosage delivered
		Carboplatin Arm Percent*	Cisplatin Arm Percent*	P-Values†
Bone Marrow
Thrombocytopenia	< 100,000/mm3	59	35	< 0.001
	< 50,000/mm3	22	11	0.006
Neutropenia	< 2,000 cells/mm3	95	97	n.s.
	< 1,000 cells/mm3	84	78	n.s.
Leukopenia	< 4,000 cells/mm3	97	97	n.s.
	< 2,000 cells/mm3	76	67	n.s.
Anemia	< 11 g/dL	88	87	n.s.
	< 8 g/dL	8	24	< 0.001
Infections		18	21	n.s.
Bleeding		6	4	n.s.
Transfusions		25	33	n.s.
Gastrointestinal
Nausea and vomiting		94	96	n.s.
Vomiting		82	91	0.007
Other GI side effects		40	48	n.s.
Neurologic
Peripheral neuropathies		13	28	0.001
Ototoxicity		12	30	< 0.001
Other sensory side effects		4	6	n.s.
Central neurotoxicity		23	29	n.s.
Renal
Serum creatinine elevations		7	38	< 0.001
Blood urea elevations		-	-	-
Hepatic
Bilirubin elevations		5	3	n.s.
SGOT elevations		23	16	n.s.
Alkaline phosphatase elevations		29	20	n.s.
Electrolytes loss
Sodium		-	-	-
Potassium		-	-	-
Calcium		-	-	-
Magnesium		58	77	< 0.001
Other side effects
Pain		54	52	n.s.
Asthenia		43	46	n.s.
Cardiovascular		23	30	n.s.
Respiratory		12	11	n.s.
Allergic		10	11	n.s.
Genitourinary		11	13	n.s.
Alopecia‡		43	57	0.009
Mucositis		6	11	n.s.

Use as Single Agent for Secondary Treatment of Advanced Ovarian Cancer: In two prospective, randomized controlled studies in patients with advanced ovarian cancer previously treated with chemotherapy, CARBOplatin for Injection USP achieved six clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71+ weeks.

INDICATIONS

Initial Treatment of Advanced Ovarian Carcinoma: CARBOplatin for Injection USP is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of CARBOplatin for Injection USP and cyclophosphamide (CYTOXAN®). Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin vs. cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES).

There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup.

Secondary Treatment of Advanced Ovarian Carcinoma: CARBOplatin for Injection USP is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.

Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.

CONTRAINDICATIONS

CARBOplatin for Injection USP is contraindicated in patients with a history of severe allergic reactions to cisplatin or other platinum-containing compounds, or mannitol.

CARBOplatin for Injection USP should not be employed in patients with severe bone marrow depression or significant bleeding.

WARNINGS

Bone marrow suppression (leukopenia, neutropenia, and thrombocytopenia) is dose-dependent and is also the dose-limiting toxicity. Peripheral blood counts should be frequently monitored during carboplatin treatment and, when appropriate, until recovery is achieved. Median nadir occurs at day 21 in patients receiving single-agent carboplatin. In general, single intermittent courses of carboplatin should not be repeated until leukocyte, neutrophil, and platelet counts have recovered.

Since anemia is cumulative, transfusions may be needed during treatment with carboplatin, particularly in patients receiving prolonged therapy.

Bone marrow suppression is increased in patients who have received prior therapy, especially regimens including cisplatin. Marrow suppression is also increased in patients with impaired kidney function. Initial carboplatin dosages in these patients should be appropriately reduced (see DOSAGE AND ADMINISTRATION) and blood counts should be carefully monitored between courses. The use of carboplatin in combination with other bone marrow suppressing therapies must be carefully managed with respect to dosage and timing in order to minimize additive effects.

Carboplatin has limited nephrotoxic potential, but concomitant treatment with aminoglycosides has resulted in increased renal and/or audiologic toxicity, and caution must be exercised when a patient receives both drugs. Clinically significant hearing loss has been reported to occur in pediatric patients when carboplatin was administered at higher than recommended doses in combination with other ototoxic agents.

Carboplatin can induce emesis, which can be more severe in patients previously receiving emetogenic therapy. The incidence and intensity of emesis have been reduced by using premedication with antiemetics. Although no conclusive efficacy data exist with the following schedules of carboplatin, lengthening the duration of single intravenous administration to 24 hours or dividing the total dose over five consecutive daily pulse doses has resulted in reduced emesis.

Although peripheral neurotoxicity is infrequent, its incidence is increased in patients older than 65 years and in patients previously treated with cisplatin. Pre-existing cisplatin-induced neurotoxicity does not worsen in about 70% of the patients receiving carboplatin as secondary treatment.

Loss of vision, which can be complete for light and colors, has been reported after the use of carboplatin with doses higher than those recommended in the package insert. Vision appears to recover totally or to a significant extent within weeks of stopping these high doses.

As in the case of other platinum coordination compounds, allergic reactions to carboplatin have been reported. These may occur within minutes of administration and should be managed with appropriate supportive therapy. There is increased risk of allergic reactions including anaphylaxis in patients previously exposed to platinum therapy. (See CONTRAINDICATIONS and ADVERSE REACTIONS: Allergic Reactions.)

High dosages of carboplatin (more than four times the recommended dose) have resulted in severe abnormalities of liver function tests.

Carboplatin may cause fetal harm when administered to a pregnant woman. Carboplatin has been shown to be embryotoxic and teratogenic in rats. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

PRECAUTIONS

General: Needles or intravenous administration sets containing aluminum parts that may come in contact with carboplatin should not be used for the preparation or administration of the drug. Aluminum can react with carboplatin causing precipitate formation and loss of potency.

ADVERSE REACTIONS

For a comparison of toxicities when carboplatin or cisplatin was given in combination with cyclophosphamide, see the COMPARATIVE TOXICITY subsection of the CLINICAL STUDIES section.

ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER

* Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: Data are based on the experience of 393 patients with ovarian cancer (regardless of baseline status) who received initial combination therapy with carboplatin and cyclophosphamide in two randomized controlled studies conducted by SWOG and NCIC (see CLINICAL STUDIES). Combination with cyclophosphamide as well as duration of treatment may be responsible for the differences that can be noted in the adverse experience table. † Single Agent Use for the Secondary Treatment of Ovarian Cancer: Data are based on the experience of 553 patients with previously treated ovarian carcinoma (regardless of baseline status) who received single-agent carboplatin.
		First Line Combination Therapy* Percent	Second Line Single Agent Therapy† Percent
Bone Marrow
Thrombocytopenia	< 100,000/mm3	66	62
	< 50,000/mm3	33	35
Neutropenia	< 2,000 cells/mm3	96	67
	< 1,000 cells/mm3	82	21
Leukopenia	< 4,000 cells/mm3	97	85
	< 2,000 cells/mm3	71	26
Anemia	< 11 g/dL	90	90
	< 8 g/dL	14	21
Infections		16	5
Bleeding		8	5
Transfusions		35	44
Gastrointestinal
Nausea and vomiting		93	92
Vomiting		83	81
Other GI side effects		46	21
Neurologic
Peripheral neuropathies		15	6
Ototoxicity		12	1
Other sensory side effects		5	1
Central neurotoxicity		26	5
Renal
Serum creatinine elevations		6	10
Blood urea elevations		17	22
Hepatic
Bilirubin elevations		5	5
SGOT elevations		20	19
Alkaline phosphatase elevations		29	37
Electrolytes loss
Sodium		10	47
Potassium		16	28
Calcium		16	31
Magnesium		61	43
Other side effects
Pain		44	23
Asthenia		41	11
Cardiovascular		19	6
Respiratory		10	6
Allergic		11	2
Genitourinary		10	2
Alopecia		49	2
Mucositis		8	1

In the narrative section that follows, the incidences of adverse events are based on data from 1,893 patients with various types of tumors who received carboplatin as single-agent therapy.

Hematologic Toxicity: Bone marrow suppression is the dose-limiting toxicity of carboplatin. Thrombocytopenia with platelet counts below 50,000/mm3 occurs in 25% of the patients (35% of pretreated ovarian cancer patients); neutropenia with granulocyte counts below 1,000/mm3 occurs in 16% of the patients (21% of pretreated ovarian cancer patients); leukopenia with WBC counts below 2,000/mm3 occurs in 15% of the patients (26% of pretreated ovarian cancer patients). The nadir usually occurs about day 21 in patients receiving single-agent therapy. By day 28, 90% of patients have platelet counts above 100,000/mm3; 74% have neutrophil counts above 2,000/mm3; 67% have leukocyte counts above 4,000/mm3.

Marrow suppression is usually more severe in patients with impaired kidney function. Patients with poor performance status have also experienced a higher incidence of severe leukopenia and thrombocytopenia.

The hematologic effects, although usually reversible, have resulted in infectious or hemorrhagic complications in 5% of the patients treated with carboplatin, with drug related death occurring in less than 1% of the patients. Fever has also been reported in patients with neutropenia.

Anemia with hemoglobin less than 11 g/dL has been observed in 71% of the patients who started therapy with a baseline above that value. The incidence of anemia increases with increasing exposure to carboplatin. Transfusions have been administered to 26% of the patients treated with carboplatin (44% of previously treated ovarian cancer patients).

Bone marrow depression may be more severe when carboplatin is combined with other bone marrow suppressing drugs or with radiotherapy.

Gastrointestinal Toxicity: Vomiting occurs in 65% of the patients (81% of previously treated ovarian cancer patients) and in about one-third of these patients it is severe. Carboplatin, as a single agent or in combination, is significantly less emetogenic than cisplatin; however, patients previously treated with emetogenic agents, especially cisplatin, appear to be more prone to vomiting.

Nausea alone occurs in an additional 10% to 15% of patients. Both nausea and vomiting usually cease within 24 hours of treatment and are often responsive to antiemetic measures. Although no conclusive efficacy data exist with the following schedules, prolonged administration of carboplatin, either by continuous 24-hour infusion or by daily pulse doses given for five consecutive days, was associated with less severe vomiting than the single dose intermittent schedule. Emesis was increased when carboplatin was used in combination with other emetogenic compounds. Other gastrointestinal effects observed frequently were pain, in 17% of the patients; diarrhea, in 6%; and constipation, also in 6%.

Neurologic Toxicity: Peripheral neuropathies have been observed in 4% of the patients receiving carboplatin (6% of pretreated ovarian cancer patients) with mild paresthesias occurring most frequently. Carboplatin therapy produces significantly fewer and less severe neurologic side effects than does therapy with cisplatin. However, patients older than 65 years and/or previously treated with cisplatin appear to have an increased risk (10%) for peripheral neuropathies. In 70% of the patients with pre-existing cisplatin-induced peripheral neurotoxicity, there was no worsening of symptoms during therapy with carboplatin.

Clinical ototoxicity and other sensory abnormalities such as visual disturbances and change in taste have been reported in only 1% of the patients. Central nervous system symptoms have been reported in 5% of the patients and appear to be most often related to the use of antiemetics.

Although the overall incidence of peripheral neurologic side effects induced by carboplatin is low, prolonged treatment, particularly in cisplatin pretreated patients, may result in cumulative neurotoxicity.

Nephrotoxicity: Development of abnormal renal function test results is uncommon, despite the fact that carboplatin, unlike cisplatin, has usually been administered without high-volume fluid hydration and/or forced diuresis. The incidences of abnormal renal function tests reported are 6% for serum creatinine and 14% for blood urea nitrogen (10% and 22%, respectively, in pretreated ovarian cancer patients). Most of these reported abnormalities have been mild and about one-half of them were reversible. Creatinine clearance has proven to be the most sensitive measure of kidney function in patients receiving carboplatin, and it appears to be the most useful test for correlating drug clearance and bone marrow suppression. Twenty-seven percent of the patients who had a baseline value of 60 mL/min or more demonstrated a reduction below this value during carboplatin therapy.

Hepatic Toxicity: The incidences of abnormal liver function tests in patients with normal baseline values were reported as follows: total bilirubin, 5%; SGOT, 15%; and alkaline phosphatase, 24%; (5%, 19%, and 37%, respectively, in pretreated ovarian cancer patients). These abnormalities have generally been mild and reversible in about one-half of the cases, although the role of metastatic tumor in the liver may complicate the assessment in many patients. In a limited series of patients receiving very high dosages of carboplatin and autologous bone marrow transplantation, severe abnormalities of liver function tests were reported.

Electrolyte Changes: The incidences of abnormally decreased serum electrolyte values reported were as follows: sodium, 29%; potassium, 20%; calcium, 22%; and magnesium, 29%; (47%, 28%, 31%, and 43%, respectively, in pretreated ovarian cancer patients). Electrolyte supplementation was not routinely administered concomitantly with carboplatin, and these electrolyte abnormalities were rarely associated with symptoms.

Allergic Reactions: Hypersensitivity to carboplatin has been reported in 2% of the patients. These allergic reactions have been similar in nature and severity to those reported with other platinum-containing compounds, i.e., rash, urticaria, erythema, pruritus, and rarely bronchospasm and hypotension. Anaphylactic reactions have been reported as part of postmarketing surveillance (see WARNINGS). These reactions have been successfully managed with standard epinephrine, corticosteroid, and antihistamine therapy.

Injection Site Reactions: Injection site reactions, including redness, swelling, and pain, have been reported during postmarketing surveillance. Necrosis associated with extravasation has also been reported.

Other Events: Pain and asthenia were the most frequently reported miscellaneous adverse effects; their relationship to the tumor and to anemia was likely. Alopecia was reported (3%). Cardiovascular, respiratory, genitourinary, and mucosal side effects have occurred in 6% or less of the patients. Cardiovascular events (cardiac failure, embolism, cerebrovascular accidents) were fatal in less than 1% of the patients and did not appear to be related to chemotherapy. Cancer-associated hemolytic uremic syndrome has been reported rarely.

Malaise, anorexia and hypertension have been reported as part of postmarketing surveillance.

OVERDOSAGE

There is no known antidote for carboplatin overdosage. The anticipated complications of overdosage would be secondary to bone marrow suppression and/or hepatic toxicity.

DOSAGE AND ADMINISTRATION

NOTE: Aluminum reacts with carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminum parts that may come in contact with the drug must not be used for the preparation or administration of CARBOplatin for Injection USP.

Single Agent Therapy: CARBOplatin for Injection USP, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 I.V. on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses of CARBOplatin for Injection USP should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.

Combination Therapy with Cyclophosphamide: In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of:

CARBOplatin for Injection USP – 300 mg/m2 I.V. on day 1 every four weeks for six cycles (alternatively see Formula Dosing).

Cyclophosphamide (CYTOXAN®) — 600 mg/m2 I.V. on day 1 every four weeks for six cycles. For directions regarding the use and administration of cyclophosphamide (CYTOXAN®) please refer to its package insert. (See CLINICAL STUDIES.)

Intermittent courses of CARBOplatin for Injection USP in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.

Dose Adjustment Recommendations: Pretreatment platelet count and performance status are important prognostic factors for severity of myelosuppression in previously treated patients.

The suggested dose adjustments for single agent or combination therapy shown in the table below are modified from controlled trials in previously treated and untreated patients with ovarian carcinoma. Blood counts were done weekly, and the recommendations are based on the lowest post-treatment platelet or neutrophil value.

* Percentages apply to CARBOplatin for Injection USP as a single agent or to both CARBOplatin for Injection USP and cyclophosphamide in combination. In the controlled studies, dosages were also adjusted at a lower level (50% to 60%) for severe myelosuppression. Escalations above 125% were not recommended for these studies.
Platelets	Neutrophilis	Adjust Dose* (From Prior Course)
> 100,000	> 2,000	125%
50-100,000	500-2,000	No Adjustment
< 50,000	< 500	75%

CARBOplatin for Injection USP is usually administered by an infusion lasting 15 minutes or longer. No pre- or post-treatment hydration or forced diuresis is required.

Patients with Impaired Kidney Function: Patients with creatinine clearance values below 60 mL/min are at increased risk of severe bone marrow suppression. In renally-impaired patients who received single agent CARBOplatin for Injection USP therapy, the incidence of severe leukopenia, neutropenia, or thrombocytopenia has been about 25% when the dosage modifications in the table below have been used.

Baseline Creatinine Clearance	Recommended Dose on Day 1
41-59 mL/min	250 mg/m2
16-40 mL/min	200 mg/m2

The data available for patients with severely impaired kidney function (creatinine clearance below 15 mL/min) are too limited to permit a recommendation for treatment.

These dosing recommendations apply to the initial course of treatment. Subsequent dosages should be adjusted according to the patient’s tolerance based on the degree of bone marrow suppression.

Formula Dosing: Another approach for determining the initial dose of CARBOplatin for Injection USP is the use of mathematical formulae, which are based on a patient’s pre-existing renal function or renal function and desired platelet nadir. Renal excretion is the major route of elimination for carboplatin. (See CLINICAL PHARMACOLOGY.) The use of dosing formulae, as compared to empirical dose calculation based on body surface area, allows compensation for patient variations in pretreatment renal function that might otherwise result in either underdosing (in patients with above average renal function) or overdosing (in patients with impaired renal function).

A simple formula for calculating dosage, based upon a patient’s glomerular filtration rate (GFR in mL/min) and CARBOplatin for Injection USP target area under the concentration versus time curve (AUC in mg/mL•min), has been proposed by Calvert. In these studies, GFR was measured by 51Cr-EDTA clearance.

PREPARATION OF INTRAVENOUS SOLUTIONS

Immediately before use, the content of each vial must be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D5W), or 0.9% Sodium Chloride Injection, USP, according to the following schedule:

Vial Strength	Diluent Volume
50 mg	5 mL
150 mg	15 mL
450 mg	45 mL

These dilutions all produce a carboplatin concentration of 10 mg/mL.

CARBOplatin for Injection USP can be further diluted to concentrations as low as 0.5 mg/mL with 5% Dextrose in Water (D5W) or 0.9% Sodium Chloride Injection, USP.

STABILITY

Unopened vials of CARBOplatin for Injection USP are stable for the life indicated on the package when stored at 25°C (77°F) [See USP Controlled Room Temperature] and protected from light.

When prepared as directed, CARBOplatin for Injection USP solutions are stable for 8 hours at room temperature (25°C). Since no antibacterial preservative is contained in the formulation, it is recommended that CARBOplatin for Injection USP solutions be discarded 8 hours after dilution.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

HOW SUPPLIED

CARBOplatin for Injection USP

NDC 50111-965-76 50 mg vials, individually cartoned, shelf packs of 10 cartons (Al cap with yellow PP cover)

NDC 50111-966-76 150 mg vials, individually cartoned, shelf packs of 10 cartons (Al cap with violet PP cover)

NDC 50111-967-76 450 mg vials, individually cartoned, shelf packs of 10 cartons (Al cap with blue PP cover)

STORAGE

Store the unopened vials at 25°C (77°F) [See USP Controlled Room Temperature]. Protect unopened vials from light. Solutions for infusion should be discarded 8 hours after preparation.

HANDLING AND DISPOSAL

Procedures for proper handling and disposal of anti-cancer drugs should be considered. Several guidelines on this subject have been published.1-7 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

REFERENCES

1. Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication No. 83-2621. For sale by the Superintendent of Documents, US Government Printing Office, Washington, DC 20402.
2. AMA Council Report. Guidelines for Handling Parenteral Antineoplastics. JAMA 1985; 253(11): 1590-1592.
3. National Study Commission on Cytotoxic Exposure–Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, ScD, Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115.
4. Clinical Oncological Society of Australia. Guidelines and Recommendations for Safe Handling of Antineoplastic Agents. Med J Australia 1983; 1:426–428.
5. Jones RB, et al: Safe Handling of Chemotherapeutic Agents: A Report from the Mount Sinai Medical Center. CA–A Cancer Journal for Clinicians 1983; (Sept/Oct) 258–263.
6. American Society of Hospital Pharmacists Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. Am J Hosp Pharm 1990; 47:1033–1049.
7. Controlling Occupational Exposure to Hazardous Drugs. (OSHA WORK PRACTICE GUIDELINES). Am J Health-Syst Pharm 1995; 52:1669-1685.

Manufactured by PLIVA – Lachema a. s., Brno, Czech Republic

for PLIVA, Inc., Pomona, NY 10970, USA

Distributed by Barr Laboratories, Inc., Pomona, NY 10970, USA

Date April 2007

Patient Information

Rx only

_____________________________________________________________________________

Read this entire leaflet carefully. Keep it for future reference.

_____________________________________________________________________________

CARBOplatin for Injection USP

This information will help you learn more about CARBOplatin for Injection USP. It cannot, however, cover all the possible warnings or side effects relating to CARBOplatin for Injection USP, and it does not list all of the benefits and risks of CARBOplatin for Injection USP. Your doctor should always be your first choice for detailed information about your medical condition and your treatment. Be sure to ask your doctor about any questions you may have.

What is cancer?

Under normal conditions, the cells in your body divide and grow in an orderly, controlled fashion. Cell division and growth are necessary for the human body to perform its functions and to repair itself. Cancer cells are different from normal cells because they are not able to control their own growth. The reasons for this abnormal growth are not yet fully understood.

A tumor is a mass of unhealthy cells that are dividing and growing fast and in an uncontrolled way. When a tumor invades surrounding healthy body tissue it is known as a malignant tumor. A malignant tumor can spread (metastasize) from its original location to other parts of the body.

What is CARBOplatin for Injection USP?

CARBOplatin for Injection USP is a medicine that is used to treat cancer of the ovaries. It acts by interfering with the division of rapidly multiplying cells, particularly cancer cells.

Who should not take CARBOplatin for Injection USP?

Treatment with CARBOplatin for Injection USP is not recommended if you:

• • • • are allergic to carboplatin or other platinum-containing products, or to mannitol;
      • have a weakened blood-forming system (bone marrow depression) or significant bleeding;
      • are pregnant, intend to become pregnant, or are breast-feeding a baby.

How is CARBOplatin for Injection USP used?

Only a professional experienced in the use of cancer drugs should give you this medication. CARBOplatin for Injection USP is given by dripping the medicine slowly and directly into a vein (intravenous infusion) for 15 minutes or longer. Your doctor will determine the dose of CARBOplatin for Injection USP for you based on your weight, height, and kidney function. Carboplatin may be given alone or with other drugs. Treatment is usually repeated every four weeks for a number of cycles.

Before and after carboplatin treatment, your doctor may give you medication to lessen the nausea and vomiting associated with this cancer treatment.

What should you tell your doctor before starting treatment with CARBOplatin for Injection USP?

Discuss the benefits and risks of CARBOplatin for Injection USP with your doctor before beginning treatment.

Be sure to inform your doctor:

• • • • If you are allergic to carboplatin or other platinum-containing products, or to mannitol;
      • If you are or intend to become pregnant, since carboplatin may harm the developing fetus. It is important to use effective birth control while you are being treated with carboplatin;
      • If you are breast-feeding, since nursing infants may be exposed to carboplatin in this way;
      • If you are taking other medicines, including all prescription and non-prescription (over-the-counter) drugs, since carboplatin may affect the action of other medicines;
      • If you have any other medical problems, especially chicken pox (including recent exposure to adults or children with chicken pox), shingles, hearing problems, infection, or kidney disease, since treatment with carboplatin increases the risk and severity of these conditions.

What should I avoid while taking CARBOplatin for Injection USP?

If you are pregnant or think you might be pregnant, or if you are breast feeding, let your doctor know right away. Carboplatin may harm your developing fetus or breast-feeding baby. If you are a woman of childbearing age, you should use birth control to avoid getting pregnant while you are taking CARBOplatin for Injection USP.

You should avoid contact with adults and children who have infections, and tell your doctor right away if you show signs of infection such as cough, fever, and/or chills. Also, while you are being treated with carboplatin or after you stop treatment, first check with your doctor before getting any immunizations (vaccinations). Avoid contact with adults or children who have received oral polio vaccine since they can pass the polio virus to you.

What are the possible side effects of CARBOplatin for Injection USP?

CARBOplatin for Injection USP may cause unwanted effects, particularly because carboplatin interferes with the growth of normal cells as well as cancer cells. For example, the occurrence of another cancer (secondary malignancy) has been reported in patients receiving cancer chemotherapy with multiple drugs. It is not always possible to tell whether such effects are caused by CARBOplatin for Injection USP, another drug you may be taking, or your illness. Because some of these effects may be serious, you will need close medical supervision during treatment with CARBOplatin for Injection USP.

The most serious side effects of CARBOplatin for Injection USP are:

• • • • bleeding and reduced blood cells, including reduced red blood cells (anemia) and platelets (needed for proper blood clotting), which may be severe enough to require blood transfusion. You should tell your doctor right away if you notice any unusual bruising or bleeding, including black tarry stools or blood in the urine.
      • infection – carboplatin can temporarily lower the number of white blood cells in your blood, increasing the risk of infection;
      • life-threatening allergic reaction – during and after treatment the doctor or nurse will observe you carefully for signs of allergic reaction;
      • kidney and liver problems;
      • loss of hearing or ringing in the ears;

Contact your doctor right away if you experience any of these effects, or notice effects that worry you or are troublesome.

Of the less serious side effects associated with carboplatin treatment, the most common are nausea, vomiting, diarrhea, loss of appetite, hair loss and numbness, tingling, burning, or pain in the hands or feet.

______________________________________________________________________________

This medicine was prescribed for your particular condition. It must be given under close medical supervision by a doctor trained in the use of drugs for the treatment of cancer.

This summary does not include everything there is to know about CARBOplatin for Injection USP. Medicines are sometimes prescribed for purposes other than those listed in patient leaflets. If you have questions or concerns, or want more information about CARBOplatin for Injection USP, your physician and pharmacist have the complete prescribing information upon which this information is based. You may want to read it and discuss it with your doctor. Remember, no written summary can replace careful discussion with your doctor.

Manufactured by PLIVA – Lachema a.s., Brno, Czech Republic

for PLIVA, Inc., Pomona, NY 10970, USA

Distributed by Barr Laboratories, Inc., Pomona, NY 10970, USA

This Patient Information Leaflet has been approved by the U.S. Food and Drug Administration. Issue Date: April 2007

I/PI/220/04/B; 70026162

(150x420) mm

04/07

PRINCIPAL DISPLAY PANEL

PRINCIPAL DISPLAY PANEL

PRINCIPAL DISPLAY PANEL